Wire open Last filed CagriSema bone density data at ObesityWeek point to a calcitonin receptor role RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire
UrgentTRLNews

Ribupatide weight loss reaches 17.7 percent in JAMA report on Phase 3 GEMINI 1 trial in China

Hengrui's once weekly GLP 1 and GIP agonist cut body weight by up to 17.7% at 48 weeks against 1.4% on placebo. Most of the gain came at the middle dose, and a few gallbladder and thyroid cases need follow up.

Editorial illustration for the story: Ribupatide weight loss reaches 17.7 percent in JAMA report on Phase 3 GEMINI 1 trial in China
Illustration: Peptide Zone. Editorial drawing, not data.

What's new

JAMA published the Phase 3 GEMINI 1 trial of once weekly ribupatide in 567 Chinese adults without diabetes, showing 10.7% to 17.7% weight loss at 48 weeks across three doses.

Why it matters

Ribupatide is a GLP 1 and GIP agonist like tirzepatide. The peer reviewed data support a filing in China and Kailera's global trials, but the top two doses gave similar results.

What's next

Hengrui has said it will seek approval in China, while Kailera Therapeutics plans global studies with higher doses and longer treatment.

Ribupatide weight loss reached an average of 17.7% at the highest dose after 48 weeks in GEMINI 1, a Phase 3 trial in China published in JAMA on November 15. The once weekly injection, made by Jiangsu Hengrui Pharmaceuticals, acts on both the GLP 1 and GIP receptors, the same pair targeted by tirzepatide. The placebo group lost 1.4%. The paper also shows that most of the benefit came at the middle dose, and it records a few safety events that later trials will need to watch.

How the GEMINI 1 trial was run

GEMINI 1 was a double blind, placebo controlled trial at 55 sites in China. It enrolled 567 adults with overweight or obesity and no diabetes between May and June 2024, and the last follow up visit took place in June 2025. Participants were split almost evenly across four arms: three dose levels of ribupatide, called low, middle and high here, and placebo. Doses were raised in steps over as long as 20 weeks before the maintenance phase, and every participant also followed a lifestyle program with diet advice and exercise goals. About 54.5% of participants were women, and 514 of them, or 90.7%, completed the full 48 weeks of treatment, which keeps the main estimate on firm ground.

The JAMA paper names Lin Zhao and Ying Chen as joint first authors. The corresponding authors are Xiaoying Li of Zhongshan Hospital at Fudan University and Hong Chen of Hengrui's clinical research group, and the trial is registered as NCT06396429. Hengrui funded the work and took part in its design, analysis and the decision to publish, even though the conflict of interest section states that none were reported. Ribupatide is also known by its development code HRS9531. Outside Greater China, the rights belong to the American company Kailera Therapeutics under a licensing deal, and Kailera, which calls the drug KAI-9531, has planned global studies of its own. Hengrui first released the headline result in July 2025, so the new paper adds the detail.

Ribupatide weight loss by dose

On the main measure, the low dose group lost 10.7% of body weight, the middle dose group 16.4% and the high dose group 17.7%. After subtracting the placebo result, the gaps were 9.3, 15.0 and 16.3 percentage points, all statistically significant. In kilograms, average losses ran from 9.8 to 16.8 against 1.6 on placebo. The step from the low to the middle dose was large, while the step from the middle to the high dose added just over one point. The share of people losing at least 5% of their weight was 88.0% on the middle dose and 85.7% on the high dose, so the two top arms were close on that count as well.

The step from the low to the middle dose was large, while the step from the middle to the high dose added just over one point.

Bigger thresholds separated the arms a little more. About 44.4% of the high dose group lost at least 20% of body weight, against 37.1% on the middle dose, 13.6% on the low dose and 3.5% on placebo. Waist size fell by 8.9 to 14.4 centimetres on the drug and by 2.5 centimetres on placebo. The authors also report better blood pressure, triglycerides, HbA1c and insulin resistance scores. The New York Post noted that weight curves in the two upper arms had not flattened by week 48, which suggests that the 48 week figure may not be the final ceiling for the drug at those doses.

Week 48 resultLow doseMiddle doseHigh dosePlacebo
Mean weight changeminus 10.7%minus 16.4%minus 17.7%minus 1.4%
Lost at least 5%68.1%88.0%85.7%16.0%
Lost at least 20%13.6%37.1%44.4%3.5%
Waist changeminus 8.9 cmminus 13.4 cmminus 14.4 cmminus 2.5 cm
Digestive side effects47.9%58.2%63.1%23.1%
Stopped for side effects0.7%0.7%1.4%0%

Safety signals in the JAMA paper

Digestive problems were the main tolerability issue, as with other drugs in this class. Nausea, vomiting and diarrhea were the most common complaints, mostly mild to moderate and clustered around dose increases. Digestive events of any kind rose with dose, from 47.9% on the low dose to 63.1% on the high dose, against 23.1% on placebo. Even so, very few people stopped because of side effects: 1.4% at most in any drug arm. Serious adverse events were no more frequent on ribupatide than on placebo, at 1.4% to 5.0% across drug arms and 5.6% on placebo. No deaths occurred during the trial, and most participants in every arm finished treatment on schedule.

Two findings deserve attention in larger and longer studies. Three people on ribupatide developed cholecystitis, an inflamed gallbladder, which is a known concern with rapid weight loss on incretin drugs. Three people on ribupatide were also diagnosed with papillary thyroid cancer. The investigators judged these cases probably unrelated to treatment, and a 48 week trial cannot settle the question either way, but it is the kind of signal regulators look at closely for GLP 1 based medicines. As always with unapproved compounds, the trial amounts were set and adjusted by investigators under medical supervision, and they are not a guide for anyone outside a study.

Comparing ribupatide with Wegovy and Mounjaro

Headlines have set the high dose result beside Wegovy, which produced an average loss of 14.9% over 68 weeks in its STEP 1 trial. That comparison needs care. The trials enrolled different populations, ran for different lengths and used different lifestyle support, and they drew participants from different countries with different starting weights and health profiles. Only a head to head trial, with the same people, timing and support in both arms, can show whether one drug beats another. Our explainer on reading weight loss trial headlines sets out why cross trial tables mislead, and the same caution applies to any comparison with tirzepatide, the closest relative of ribupatide.

The next steps run on two tracks. Hengrui said in 2025 that it would seek approval in China, and the JAMA paper now gives regulators and doctors there a peer reviewed record of the main data. Kailera has said its studies outside China will test higher doses over a longer treatment period. Until those studies report, published Phase 3 ribupatide weight loss figures come only from adults in China, as the title of the JAMA paper makes clear. The broader race among dual and triple agonists is mapped in our coverage of retatrutide in Phase 3, which set a high bar for average weight loss in a separate trial program.

Conclusion

GEMINI 1 gives ribupatide weight loss data a peer reviewed footing: up to 17.7% at 48 weeks against 1.4% on placebo, with most of the gain already reached at the middle dose. Digestive side effects were common but rarely led people to stop. Gallbladder and thyroid findings, though few, need follow up in longer trials. Comparisons with Wegovy or Mounjaro remain indirect until the drugs meet in the same study.

More from the wire

Same thread first, then the same desk.